Healthcare / Drug Manufacturers - Specialty & GenericKSE
$10080.00
-330.00 (-3.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-8.3B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$153.9B
P/E
11.8x
↓EV/EBITDA
3.9x
↓ROE
3.2%
↑Gross Margin
34.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.7%
FCF CAGR
—
FCF margin
1.1%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $255.21B · net income $13.60B · FCF $2.86B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $255.21B | $255.21B | $259.60B | $230.39B | $198.93B |
| Net Income | $13.60B | $13.60B | $23.38B | $29.77B | $23.92B |
| EBITDA | $24.82B | $24.82B | $35.45B | $40.48B | $34.71B |
| EPS | 857.00 | 857.00 | 1531.00 | 1950.00 | 1567.00 |
| Gross Margin | 34.1% | 34.1% | 36.1% | 43.0% | 49.7% |
| Operating Margin | 5.1% | 5.1% | 8.3% | 13.1% | 15.0% |
| Net Margin | 5.3% | 5.3% | 9.0% | 12.9% | 12.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.10 | 4.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.86B | $2.86B | $-8.69B | $-8.29B | $-50.91B |
| Returns | |||||
| ROE | 3.2% | 3.2% | 6.2% | 8.3% | 7.2% |
| Valuation | |||||
| P/E | 11.76 | 11.76 | 7.81 | 7.80 | 11.17 |
| EV/EBITDA | 3.91 | 3.91 | 3.94 | 4.63 | 6.64 |
| P/B | 0.38 | 0.38 | 0.49 | 0.65 | 0.80 |
| Growth & Yield | |||||
| Revenue Growth | -1.7% | -1.7% | 12.7% | 15.8% | — |
| EPS Growth | -44.0% | -44.0% | -21.5% | 24.4% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.4%
EPS terminal req.
$894.43
Spread vs growth
-45.5%
5Y implied EPS CAGR
4.8%
EPS terminal req.
$1082.26
Spread vs growth
-48.8%
10Y implied EPS CAGR
7.4%
EPS terminal req.
$1742.99
Spread vs growth
-51.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.1%
Start / end P/E
7.4x → 11.8x
EPS bridge
1531.00 → 857.00
Residual
-25.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.